Tofogliflozin Hydrate

托格列净

Report date: 2022/08/17 12:43:21
NME

Base Information

Drug NameTofogliflozin Hydrate
Drug Alias NametofogliflozinatofogliflozinumtofogliflozineDeberzaApleway +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium/glucose cotransporter 2 inhibitors
TargetsSodium/glucose cotransporter 2
Therapy Area/IndicationsDiabetes Mellitus, Type 2Metabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2014/03/24
Country/TerritoryCanadaUnited StatesRomania +[15] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesChugai Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSanofiKowa Research Institute IncKowa Dental Health Co Ltd +[4] 
Inactive CompaniesF. Hoffmann-La Roche Ltd
Active IndicationsDiabetes Mellitus, Type 2Metabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeA10BH
Related LinksWikipediaDrugBankKEGG